Evidence map›Paper›PMID 42245692›Full record

ArticleFrontiers in oncology2026

Case Report: Patient-derived organoids guiding dabrafenib-trametinib therapy in BRAF

Caifeng Gong, Yang Yang, Qi Yan, Weiting Zhao, Minghao Zhang, Wen Zhang, Shuhui You, Ruihong Yin, Yang Huang, Yunshan Zhao and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Caifeng Gong *Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yang Yang *Darkjade Sciences, Inc., Beijing, China.
Qi Yan *Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Weiting ZhaoDarkjade Sciences, Inc., Beijing, China.
Minghao ZhangDarkjade Sciences, Inc., Beijing, China.
Wen ZhangDepartment of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shuhui YouDepartment of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ruihong YinDarkjade Sciences, Inc., Beijing, China.
Yang HuangDarkjade Sciences, Inc., Beijing, China.
Yunshan ZhaoDarkjade Sciences, Inc., Beijing, China.
Aiping ZhouDepartment of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: BRAF Case presentation: A patient with rapidly progressive BRAF Conclusion: This case suggests that dual BRAF-MEK inhibition may represent a feasible precision treatment option for patients with BRAF

Indexed as

BRAF kinase inhibitororganoidspreclinical modelstomach neoplasmstargeted therapy

Identifiers

PMID42245692
PMCPMC13229687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.